# Bausch + Lomb Corporation (BLCO) Stock Analysis: Exploring the 12% Upside Potential in Eye Health

- Link: https://www.directorstalkinterviews.com/bausch-lomb-corporation-blco-stock-analysis-exploring-the-12-upside-potential-in-eye-health/4121251887
- Published: 2026-05-18T10:23:08+01:00
- Author: Madison Wilson

Investors with an eye on the healthcare sector may find Bausch + Lomb Corporation(
NYSE: BLCO) an intriguing opportunity. With a market capitalization of $5.74 billion,
this Canadian company has established itself as a significant player in the Medical
Instruments & Supplies industry. Specializing in eye health, Bausch + Lomb operates
across multiple segments including Vision Care, Pharmaceuticals, and Surgical, offering
a comprehensive suite of products and services worldwide.

The stock currently trades at $16.09, with a slight price change of -0.18 (-0.01%).
It has experienced a range between $11.19 and $18.60 over the past 52 weeks. Analysts
have set a target price range between $16.00 and $21.00, with an average target 
of $18.04, indicating a potential upside of approximately 12.11%. This could be 
a promising sign for investors looking for growth within the eye health sector.

From a valuation perspective, Bausch + Lomb’s Forward P/E ratio stands at 15.13,
providing a glimpse into the company’s earnings expectations relative to its current
stock price. However, other valuation metrics such as the Price/Earnings (P/E) ratio,
Price/Book, and Price/Sales remain unavailable, which might suggest a need for investors
to dig deeper into the company’s financial health and growth projections.

The company’s performance metrics reveal a revenue growth of 9.40%, a positive indicator
in a competitive industry. However, with an EPS of -0.62 and a Return on Equity 
of -3.28%, the company faces challenges in profitability. Despite these hurdles,
Bausch + Lomb generated a free cash flow of $238.5 million, demonstrating its ability
to generate cash to support operations and potential investments in growth strategies.

Analyst sentiment towards Bausch + Lomb is mixed, with 4 buy ratings, 9 hold ratings,
and 1 sell rating. This diverse outlook reflects the potential and risks inherent
in the company. Investors should consider the broader market trends and individual
company performance when evaluating such a mixed analyst consensus.

From a technical standpoint, the stock’s 50-day moving average is at $16.24, while
the 200-day moving average is $16.00. The Relative Strength Index (RSI) sits at 
54.05, indicating neither overbought nor oversold conditions. The MACD and signal
line figures suggest a neutral stance, reinforcing the notion of stability with 
potential for upward momentum.

Bausch + Lomb’s lack of dividend yield and a payout ratio of 0.00% suggest that 
the company may be reinvesting earnings to fuel growth rather than providing immediate
returns to shareholders. This strategy could appeal to investors with a long-term
growth focus.

Operating as a subsidiary of Bausch Health Companies Inc., Bausch + Lomb has a rich
history dating back to 1853. The company’s extensive global presence and diversified
product offerings in eye health position it uniquely in the healthcare industry.
With a focus on innovation and expansion, Bausch + Lomb remains committed to addressing
the diverse needs of its international customer base.

For investors exploring healthcare opportunities, Bausch + Lomb Corporation presents
a compelling case. The potential upside, combined with its strategic market positioning
and cash flow generation, makes it a stock worth watching closely. As the eye health
industry continues to evolve, Bausch + Lomb’s role as a market leader offers both
challenges and opportunities in equal measure.

Share on: